Hpgc Renmintongtai Pharmaceutical600829.SHValuation Analysis

As of Oct 19, 2026, Hpgc Renmintongtai Pharmaceutical (600829.SH) trades at a P/E of 36.50x, P/B of 1.68x, P/S of 0.48x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 84th percentile over the trailing 10Y window (vs. 66th percentile over 3Y); P/B sits at the 38th percentile over the trailing 10Y window (vs. 65th percentile over 3Y); P/S sits at the 52nd percentile over the trailing 10Y window (vs. 70th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 49th percentile within its industry and the 49th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/E and P/B percentiles diverge here, differing by 46.7 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Hpgc Renmintongtai Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.